Allakos Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLK research report →
Range $1 – $218
Price Chart
About the company
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions.
- CEO
- Robert Alexander
- IPO
- 2018
- Employees
- 131
- HQ
- San Carlos, CA, US
Get TickerSpark's AI analysis on ALLK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.74M
- P/E
- -0.25
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.37
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -93.54%
- ROIC
- -140.27%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-7,724,000-25.8%
- Op Income
- $-122,225,000
- Net Income
- $-115,818,000+37.6%
- EPS
- $-1.30+39.3%
- OCF Growth
- +19.6%
- FCF Growth
- +19.9%
- 52W High
- $1.56
- 52W Low
- $0.22
- 50D MA
- $0.27
- 200D MA
- $0.74
- Beta
- 0.14
- RSI (14)
- 62
- Avg Volume
- 2.85M
No earnings-call transcripts are available for ALLK yet.
- Free Float
- 63.9%
- Shares Outstanding
- 90.38M
- Float Shares
- 57.74M
of shares held by institutions
80 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 1.27M | ▼ 3.45M |
| Point72 Middle East Fze | 10.57K | ▲ 10.57K |
Held by 1 ETFs
Biggest fund positions in ALLK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 25 | BVF PARTNERS L P/IL | sell | 855,211 |
| May 15, 25 | Walker Paul Edward | sell | 3,386,400 |
| May 15, 25 | Walker Paul Edward | sell | 37,600 |
| May 15, 25 | Walker Paul Edward | sell | 16,000 |
| May 15, 25 | Walker Paul Edward | sell | 7,700 |
| May 15, 25 | Walker Paul Edward | sell | 7,700 |
| May 15, 25 | Walker Paul Edward | sell | 99,590 |
| May 15, 25 | Walker Paul Edward | sell | 86,762 |
| May 15, 25 | Walker Paul Edward | sell | 41,000 |
| May 15, 25 | Tomasi Adam | sell | 1,200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALLK coverage
Recent articles, reports, and earnings notes.
No research on ALLK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALLK report →$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
prnewswire.com · Apr 2
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
businesswire.com · Apr 2
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
businesswire.com · Apr 2
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
globenewswire.com · Apr 2
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
globenewswire.com · Mar 12
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
globenewswire.com · Feb 11
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
globenewswire.com · Feb 10
Why Is Allakos Stock Plunging On Monday?
benzinga.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.